Merck KGaA Invests in Research Partnerships in Israel - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Invests in Research Partnerships in Israel


Newly created company Metabomed and start-up company ChanBio joined Neviah Genomics and Merck KGaA in Merck’s Bioincubator located in Yavne, Israel, the company announced in a press release. The EUR 10 million ($13.7 million) Israel Bioincubator Fund was launched in 2011 by MS Ventures, the corporate venture arm of the prescription medicines division of Merck KGaA. The fund is focused on pre-seed and seed opportunities originating in Israel.

Merck KGaA is increasingly counting on partnerships with Israeli biotechnology companies, as demonstrated by its cooperation with Metabomed and ChanBio, the company said in the press release. Metabomed focuses on research in the field of cancer metabolism and computational biology. ChanBio will concentrate on the discovery of antibodies selective for ion channels considered to be significant therapeutic targets for the treatment of multiple sclerosis.

The biopharmaceutical division of Merck KGaA signed a memorandum of understanding earlier in November with Israel biotech company Kadimastem, which develops human pluripotent stem cell-related products. The aim is to utilize their screening platform to characterize new compounds discovered as remyelinating agents for multiple sclerosis, but also to possibly extend the collaboration into research fields such as amyotrophic lateral sclerosis. This agreement follows the signature of a previous agreement with Kadimastem in 2012.

Source: Merck

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here